KCT0007644招募中未知
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (CLAUDIA Colon Cancer, KCSG CO22-12) Part 2: A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients with Positive MRD after Curative Resection
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 236
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 75(Year)（—）
- 性别
- All
入选标准
- •1.Patients who willingly consented and signed the informed consent form to participate in the study
- •2.Age range of 19 to 75 years
- •3.Adenocarcinoma of colon confirmed by histology
- •4.Patients with stage II-III colon cancer as defined by the American Joint Committee on Cancer's eighth edition (Stage II cancer is limited to patients who are at a high risk, with more than one risk factor for recurrence.)
- •5.Patients who have completed the sixth cycle of FOLFOX or the fourth cycle of CAPOX adjuvant chemotherapy for colon cancer following radical resection (R0 resection)
- •6.A ctDNA test performed three 3 to 6 weeks following surgery reveals a positive MRD
- •7.ECOG performance scale of 0-1 (only 1 is allowed for 70-75 years old)
- •8.Adequate bone marrow function [ANC =1,300/LL, platelets =75,000/LL, hemoglobin =8.0g/dL (may be eligible in study if intermittent transfusion is required)]
- •9.Appropriate liver function (total bilirubin =1.5xULN, AST and ALT =3xULN)
- •10.Appropriate renal function (serum creatine =1.5xULN, renal clearance rate =50 ml/min)
- •11.Patients who are deemed to understand the study protocol and are willing to participate in the trial until it is completed
排除标准
- •1.Pregnant or lactating women
- •2.Pregnant women who had a positive pregnancy test at the time of the baseline examination (postmenopausal women must be amenable for at least 12 months to be considered non-fertility)
- •3.Sexually active men and women of reproductive age who are unwilling to use contraception throughout the study treatment and for a period of 6 months (female) or 3 months (male) following the discontinuation of study treatment
- •4.Clinically significant heart condition [unstable angina requiring medication, symptomatic coronary artery disease, congestive heart failure, or significant heart arrhythmia above NYHA II, or acute coronary syndrome, including myocardial infarction within the last 6 months]
- •5.Active viral infections such as HIV (However, HBV carriers may enroll if their HBV DNA titer is less than 20,000 IU/ml, and antiviral drugs for hepatitis B may be administered prophylactically at the investigator’s discretion)
- •6.Significant uncontrolled infections or other uncontrolled comorbidities
- •7.Symptomatic inflammatory bowel disease
- •8.Allogeneic transplantation history necessitating immunosuppressive therapy
- •9.A history of other malignancies identified within the last three years, except for completed removed basal cell carcinoma of the skin, completely removed cervical epithelial carcinoma, and thyroid cancer that has been treated, including surgery
- •10.Recurrent or residual disease identified clinically or radiographically
- •11.Previous history of irinotecan treatment
- •12.Polyposis including familial adenomatous polyps
- •13.Two or more colon or rectal cancers with a pathologic stage greater than II that were detected concurrently or within the last three years
- •14.When the investigator determines that the subjects' safety may be jeopardized during the study because of other serious or unstable pre-existing medical or mental conditions
- •15.Prior clinical trial participation and usage of investigational drugs or devices following radical resection of colon cancer
- •16.Patients with peripheral neuropathy who have a CTCAE v5 grade 3 or higher functional disability (corresponds to severe symptoms, limiting self-care activity of daily living according to CTCAE v5 criteria)
- •17.Previous anaphylactic reaction or severe and unexpected reactions to fluoropyrimidines or platinum
- •18.Gilbert's syndrome, dehydro-pyridine dehydrogenase (DPD) deficiency, or homozygous UGT1A1*28 alleles
研究者
相似试验
招募中
不适用
Multicenter Study of Circulating Tumor DNA in Patients with Pancreatic Cancer Using a Personalized PanelResectable and unresectable pancreatic cancerJPRN-UMIN000043561ational Cancer Center Hospital East150
进行中（未招募）
4 期
CUARTET StudyMetastatic Castration-sensitive Prostate CancerJPRN-jRCTs071200040emura Hirotsugu100
招募中
不适用
Observational Study of circulating-tumor DNA in Patients with Gastrointestinal CancerEsophageal cancer, Esophago-gastric junctional cancer, Gastric cancerJPRN-UMIN000042003ational Cancer Center Hospital East200
招募中
不适用
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancerNL-OMON24467Erasmus Medical Center95
已完成
不适用
Quantification of Circulating tumor DNA derived Structural variants to assess treatment response in metastatic prostate cancer patientsprostate carcinoma10038364prostate cancerNL-OMON43524Erasmus MC, Universitair Medisch Centrum Rotterdam285